Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations
Molecules · 2024
DOI: 10.3390/molecules29061229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Zhenya Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau Institute for Ap…. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Macau University of Science and Technology, the Science and Technology Development Fund, Macau SAR, Science and Technology Development Fund, Macau SAR.
Abstract (Originalsprache)
The development of effective inhibitors targeting the Kirsten rat sarcoma viral proto-oncogene (KRASG12D) mutation, a prevalent oncogenic driver in cancer, represents a significant unmet need in precision medicine. In this study, an integrated computational approach combining structure-based virtual screening and molecular dynamics simulation was employed to identify novel noncovalent inhibitors targeting the KRASG12D variant. Through virtual screening of over 1.7 million diverse compounds, potential lead compounds with high binding affinity and specificity were identified using molecular docking and scoring techniques. Subsequently, 200 ns molecular dynamics simulations provided critical insights into the dynamic behavior, stability, and conformational changes of the inhibitor-KRASG12D complexes, facilitating the selection of lead compounds with robust binding profiles. Additionally, in silico absorption, distribution, metabolism, excretion (ADME) profiling, and toxicity predictions were applied to prioritize the lead compounds for further experimental validation. The discovered noncovalent KRASG12D inhibitors exhibit promises as potential candidates for targeted therapy against KRASG12D-driven cancers. This comprehensive computational framework not only expedites the discovery of novel KRASG12D inhibitors but also provides valuable insights for the development of precision treatments tailored to this oncogenic mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Quality Research in Chinese Medicine, Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau Institute for Applied Research in Medicine and Health, Faculty of Chinese Medicine, Ma…
- Teaching and Research Department of Public Medical Courses, School of Nursing, Guangzhou Xinhua University, Guangzhou 510520, China.
- School of Materials Science and Engineering, National Institute for Advanced Materials, Renewable Energy Conversion and Storage Center (RECAST), Nankai University, Tianjin 300350, China.
ORCID-Profile: Qibiao Wu, Guankui Long
Förderung
- Macau University of Science and Technology
- the Science and Technology Development Fund, Macau SAR
- Science and Technology Development Fund, Macau SAR
- Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and…
Zitieren
APA
Du, Z., Tu, G., Gong, Y., Fu, X., Wu, Q., & Long, G. (2024). Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations. Molecules. https://doi.org/10.3390/molecules29061229
Vancouver
Du Z, Tu G, Gong Y, Fu X, Wu Q, Long G. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations. Molecules. 2024. doi:10.3390/molecules29061229
BibTeX
@article{Du2024,
author = {Du, Zhenya and Tu, Gao and Gong, Yaguo and Fu, Xiangzheng and Wu, Qibiao and Long, Guankui},
title = {Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29061229}
}
EUVIMED